DADavid C. Alexander

David C. Alexander

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David C. Alexander has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mycobacterium xenopi Genotype Associated with Clinical Phenotype in Lung Disease

    by Takashi Hirama, Alex Marchand-Austin, Jennifer Ma, David C. Alexander, Sarah K. Brode, Theodore K. Marras, Frances B. Jamieson

    Mycobacterium xenopi is responsible for pulmonary disease (PD) in Europe and Canada. Despite its high prevalence and increasing clinical importance, little is known about the genetic diversity of M. xenopi. Through a prospective study for M. xenopi strain type and the relation to clinical phenotype, 39 patients with M. xenopi PD were analyzed. Our study demonstrated that sequence type (ST) 5 was dominant in Ontario among 15 distinct STs and caused PD in people even without underlying lung disease, whereas disease due to non-ST5 was found almost exclusively in patients with underlying lung disease.


  • Open Access

    Novel genome polymorphisms in BCG vaccine strains and impact on efficacy

    by Andrea S Leung, Vanessa Tran, Zuowei Wu, Xuping Yu, David C Alexander, George Fu Gao, Baoli Zhu, Jun Liu

    Bacille Calmette-Guérin (BCG) is an attenuated strain ofMycobacterium boviscurrently used as a vaccine against tuberculosis. Global distribution and propagation of BCG has contributed to thein vitroevolution of the vaccine strain and is thought to partially account for the different outcomes of BCG vaccine trials. Previous efforts by several molecular techniques effectively identified large sequence polymorphisms among BCG daughter strains, but lacked the resolution to identify smaller changes. In this study, we have used a NimbleGen tiling array for whole genome comparison of 13 BCG strains. Using this approach, in tandem with DNA resequencing, we have identified six novel large sequence polymorphisms including four deletions and two duplications in specific BCG strains. Moreover, we have uncovered various polymorphisms in thephoP-phoRlocus. Importantly, these polymorphisms affect genes encoding established virulence factors including cell wall complex lipids, ESX secretion systems, and the PhoP-PhoR two-component system. Our study demonstrates that major virulence factors are different among BCG strains, which provide molecular mechanisms for important vaccine phenotypes including adverse effect profile, tuberculin reactivity and protective efficacy. These findings have important implications for the development of a new generation of vaccines.